You just read:

InMed Pharmaceuticals Announces Transition to a Single Cannabinoid Investigational Drug Candidate - INM-755 - for its Epidermolysis Bullosa Program

News provided by

InMed Pharmaceuticals Inc.

Mar 13, 2019, 07:25 ET